Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.Products:General pharmaceutical tablets and capsulesOral liquidsExternal preparationsSterile ophthalmic ointmentsThe company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.As of July 31, 2025, the company has 95 permanent employees.Competitive Strengths:Experienced Promoters and Management TeamWide range of ProductsStrategic Location of Manufacturing FacilityScalable Business ModelQuality assurance
| Category | Shares Offered* | Total Amt* (₹ Cr.) |
|---|---|---|
|
Anchor
|
108,000 | ₹1.380 |
|
QIB (Ex Anchor)
|
1,017,000 | ₹13.020 |
|
NII
|
309,000 | ₹3.960 |
|
Retail
|
716,000 | ₹9.160 |
| Total ** | 2,150,000 | ₹27.520 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 2,000 | ₹256,000 |
| Retail (Max — 13 Lots) | 13 | 13,000 | ₹1,664,000 |
| S-HNI (Min — 14 Lots) | 14 | 14,000 | ₹1,792,000 |
| S-HNI (Max — 66 Lots) | 66 | 66,000 | ₹8,448,000 |
| B-HNI (Min — 67 Lots) | 67 | 67,000 | ₹8,576,000 |
| Category | QIB | NII | Retail | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor Investor | Total QIB | Below ₹10L | Above ₹10L | Total NII | |||
| Allocation (No. of shares) | — | — | — | — | — | 309,000 | 716,000 | 1,025,000 |
| Allotment price (Rs.) | 128 | 128 | 128 | 128 | 128 | 128 | 128 | 128 |
| No. of applications | — | — | — | — | — | — | — | — |
| No. of shares applied | — | — | — | — | — | — | — | — |
| Amount collected (Rs.cr.) | 13.02 | 1.38 | 14.40 | — | — | 3.96 | 9.16 | 27.52 |
| No. of times subscribed | — | — | — | — | — | — | — | — |
| No. of shares allotted | — | — | — | — | — | 309,000 | 716,000 | 1,025,000 |
| Amount (Rs.cr.) | 13.02 | 1.38 | 14.40 | — | — | 3.96 | 9.16 | 13.12 |
| No. of allottees | — | — | — | — | — | — | — | — |
| Category | Shares Offered | Amt (₹ Cr) | Size (%) |
|---|---|---|---|
| Anchor / Market Maker | 108,000 | ₹1.38 |
5.02%
|
| QIB (Ex Anchor) | 1,017,000 | ₹13.02 |
47.30%
|
| NII / HNI | 309,000 | ₹3.96 |
14.37%
|
| Retail (RII) | 716,000 | ₹9.16 |
33.30%
|
| Total | 2,150,000 | ₹27.52 |
100.00%
|
| Particulars | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue from Operations | 19.51 | 49.65 | 35.87 |
| EBITDA | 4.24 | 9.54 | 8.39 |
| Profit After Tax (PAT) | 2.87 | 6.11 | 4.87 |
| Net Worth | 19.10 | 16.23 | 5.87 |
| Total Assets | 56.29 | 42.53 | 33.88 |
| Reserves & Surplus | 13.16 | 10.29 | 5.37 |
| Total Borrowings | 15.32 | 15.62 | 17.09 |
| EBITDA Margin (%) | 19.41% | — | — |
| PAT Margin (%) | 12.43% | — | — |
Curis Lifesciences Ltd. proposes to utilize the net proceeds raised through this IPO for the following objects as stated in the Draft Red Herring Prospectus (DRHP) filed with SEBI: